New study explores racial disparity in HBV treatment initiation
April 11th 2023The cumulative probabilities of treatment initiation after meeting the criteria was not significantly different between the different racial groups and the incidence of major adverse liver outcomes was 0.1 per 100 person-years and did not differ by race.
Tofacitinib-treated women with PsA less likely to achieve MDA
April 4th 2023At month 3, patients treated with tofacitinib achieved higher rates of ACR20/50, MDA, and PASI75 in both sexes when compared with the placebo. However, female patients were less likely to achieve MDA when compared with males.